Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00207688 · ClinicalTrials.gov registry record
A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 505
- Enrollment target
NCT00207688 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 505 participants.
The verdict
NCT00207688 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 505 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate long-term safety information of infliximab in patients who have participated in infliximab clinical studies in ulcerative colitis.
Interventions
- DRUG Placebo
- DRUG Infliximab 5 mg/kg
- DRUG Infliximab 10 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 505 participants |
| Start Date | 2004-08-31 |
| Est. Completion | 2015-09-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00207688
The ClinicalTrials.gov registry entry for NCT00207688 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 505 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00207688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00207688 about?
NCT00207688 is a clinical study titled "A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients". The purpose of this study is to evaluate long-term safety information of infliximab in patients who have participated in infliximab clinical studies in ulcerative colitis.
What is the current status of trial NCT00207688?
This trial is currently completed. The enrollment target is 505 participants. The study started on 2004-08-31. Estimated completion is 2015-09-09.
What interventions are being tested in trial NCT00207688?
The interventions under investigation include: Placebo (DRUG), Infliximab 5 mg/kg (DRUG), Infliximab 10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT00207688?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.